Oncology Research & Treatment (ehemals: Onkologie)
| Erscheinungsweise | 12x im Jahr |
| Liefertermin | Liefertermin des ersten Heftes in 5-10 Werktagen (bei rückwirkenden Abos; ansonsten 2-8 Tage nach Erscheinen des nächsten Heftes). Lieferzeit für Folgehefte 1-3 Werktage nach Erscheinen. |
| Mindestlaufzeit | Mindestlaufzeit des Abos: 12 Monate |
| Kündigungsfrist | bis 31.10. zum Jahresende |
| Verlag | Karger Verlag |
| ISSN | 0378584X |
| Artikel-Nr. | 5186 |
Produktbeschreibung
Your source for important clinical and translational laboratory studies from around the world
Although laboratory and clinical cancer research need to be closely linked, observations at the basic level often remain removed from medical applications. This journal works to accelerate the translation of experimental results into the clinic, and back again into the laboratory for further investigation. The fundamental purpose of this effort is to advance clinically-relevant knowledge of cancer, and improve the outcome of prevention, diagnosis and treatment of malignant disease. The journal publishes significant clinical studies from cancer programs around the world, along with important translational laboratory findings, mini-reviews (invited and submitted) and in-depth discussions of evolving and controversial topics in the oncology arena. A unique feature of the journal is a new section which focuses on rapid peer-review and subsequent publication of short reports of phase 1 and phase 2 clinical cancer trials, with a goal of insuring that high-quality clinical cancer research quickly enters the public domain, regardless of the trial’s ultimate conclusions regarding efficacy or toxicity.
Although laboratory and clinical cancer research need to be closely linked, observations at the basic level often remain removed from medical applications. This journal works to accelerate the translation of experimental results into the clinic, and back again into the laboratory for further investigation. The fundamental purpose of this effort is to advance clinically-relevant knowledge of cancer, and improve the outcome of prevention, diagnosis and treatment of malignant disease. The journal publishes significant clinical studies from cancer programs around the world, along with important translational laboratory findings, mini-reviews (invited and submitted) and in-depth discussions of evolving and controversial topics in the oncology arena. A unique feature of the journal is a new section which focuses on rapid peer-review and subsequent publication of short reports of phase 1 and phase 2 clinical cancer trials, with a goal of insuring that high-quality clinical cancer research quickly enters the public domain, regardless of the trial’s ultimate conclusions regarding efficacy or toxicity.
